BCAX
Bicara Therapeutics Inc. Common Stock
NASDAQ: BCAX · HEALTHCARE · BIOTECHNOLOGY
$22.92
-2.01% today
Updated 2026-06-05
Market cap
$1.35B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.77
Dividend yield
—
52W range
$8 – $24
Volume
0.5M
WallStSmart proprietary scores
28
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.0
Quality
A3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
6.9
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$31.46
+37.26%
12-Month target
$18.67
-18.54%
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy9 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 6.89 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-37.57M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-37.84M | $-51.98M | $-68.00M | $-137.95M | $-56.21M |
| EPS | — | — | — | — | $-2.77 |
| Free cash flow | $-32.27M | $-46.21M | $-74.82M | $-107.11M | $-37.57M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Bicara Therapeutics Inc. Common Stock trades at $22.92. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 6.89, it sits in the safe zone.
Frequently asked questions
What is Bicara Therapeutics Inc. Common Stock's stock price?
Bicara Therapeutics Inc. Common Stock (BCAX) trades at $22.92.
Is Bicara Therapeutics Inc. Common Stock overvalued?
Bicara Therapeutics Inc. Common Stock carries a Smart Value Score of 28/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Bicara Therapeutics Inc. Common Stock (BCAX)?
The 12-month analyst consensus target is $31.46, about 37.3% above the current $22.92. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Bicara Therapeutics Inc. Common Stock's Altman Z-Score is 6.89, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-39.06%
Beta—
50D MA$21.45
200D MA$17.27
Shares out0.07B
Float0.04B
Short ratio—
Avg volume0.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—